Progression-free survival, overall survival and immunophenotyping outcomes for patients with stage III-IV head and neck cancer and cisplatin contraindication treated with definitive radiotherapy plus pembrolizumab

Category Primary study
ConferenceInternational journal of radiation oncology biology physics
Year 2020
This article has no abstract
Epistemonikos ID: 9227ccc205b4f0f4c08dbb09497da8a4a3e57cc2
First added on: Feb 11, 2025